Clonal hematopoiesis in the donor does not adversely affect long-term outcomes following allogeneic hematopoietic stem cell transplantation: result from a 13-year follow-up

• Published in: Haematologica (Roma) 2023-07, Vol.108 (7), p.1817-1826
• Main Authors: Kim, Kyoung Ha, Kim, TaeHyung, Novitzky-Basso, Igor, Lee, Hyewon, Yoo, Youngseok, Ahn, Jae-Sook, Pasic, Ivan, Law, Arjun, Lam, Wilson, Michelis, Fotios V, Gerbitz, Armin, Viswabandya, Auro, Lipton, Jeffrey, Kumar, Rajat, Mattsson, Jonas, Zhang, Zhaolei, Kaushansky, Nathali, Brilon, Yardena, Chapal-Ilani, Noa, Biezuner, Tamir, Shlush, Liran I, Kim, Dennis Dong Hwan
• Format: Article
• Language: English
• Subjects: Bone Marrow Transplantation; Clonal Hematopoiesis; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation - methods; Humans; Medicin och hälsovetenskap; Transplantation, Homologous - adverse effects
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2022.281806

Donor clonal hematopoiesis may be transferred to the recipient through allogeneic hematopoietic stem cell transplantation (HSCT), but the potential for adverse long-term impact on transplant outcomes remains unknown. A total of 744 samples from 372 recipients who received HSCT and the corresponding donors were included. Bar-coded error-corrected sequencing using a modified molecular inversion probe capture protocol was performed, which targeted 33 genes covering mutations involved in clonal hematopoiesis with indeterminate potential (CHIP) and other acute myeloid leukemia-related mutations. A total of 30 mutations were detected from 25 donors (6.7%): the most frequently mutated gene was TET2 (n=7, 28%), followed by DNMT3A (n=4, 16%), SMC3 (n=3, 12%) and SF3B1 (n=3, 12%). With a median follow-up duration of 13 years among survivors, the presence of CHIP in the donor was not associated with recipient overall survival (P=0.969), relapse incidence (P=0.600) or non-relapse mortality (P=0.570). Donor CHIP did not impair neutrophil (P=0.460) or platelet (P=0.250) engraftment, the rates of acute (P=0.490), or chronic graft-versus-host disease (P=0.220). No significant difference was noted for secondary malignancy following HSCT between the two groups. The present study suggests that the presence of CHIP in allogeneic stem donors does not adversely affect transplant outcomes after HSCT. Accordingly, further study is warranted to reach a clearer conclusion on whether molecular profiling to determine the presence of CHIP mutations is necessary for the pretransplant evaluation of donors prior to stem cell donation.